IL287053A - A method for the treatment of Duchenne muscular dystrophy-mediated nonsense mutation in medical patients - Google Patents

A method for the treatment of Duchenne muscular dystrophy-mediated nonsense mutation in medical patients

Info

Publication number
IL287053A
IL287053A IL287053A IL28705321A IL287053A IL 287053 A IL287053 A IL 287053A IL 287053 A IL287053 A IL 287053A IL 28705321 A IL28705321 A IL 28705321A IL 287053 A IL287053 A IL 287053A
Authority
IL
Israel
Prior art keywords
treating
muscular dystrophy
duchenne muscular
nonsense mutation
pediatric patients
Prior art date
Application number
IL287053A
Other languages
English (en)
Hebrew (he)
Inventor
Ronald Kong
Joseph William Mcintosh
Original Assignee
Ptc Therapeutics Inc
Ronald Kong
Joseph William Mcintosh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Inc, Ronald Kong, Joseph William Mcintosh filed Critical Ptc Therapeutics Inc
Publication of IL287053A publication Critical patent/IL287053A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
IL287053A 2019-04-10 2021-10-06 A method for the treatment of Duchenne muscular dystrophy-mediated nonsense mutation in medical patients IL287053A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962831931P 2019-04-10 2019-04-10
PCT/US2020/027382 WO2020210432A1 (en) 2019-04-10 2020-04-09 Method for treating nonsense mutation mediated duchenne muscular dystrophy in pediatric patients

Publications (1)

Publication Number Publication Date
IL287053A true IL287053A (en) 2021-12-01

Family

ID=72751530

Family Applications (1)

Application Number Title Priority Date Filing Date
IL287053A IL287053A (en) 2019-04-10 2021-10-06 A method for the treatment of Duchenne muscular dystrophy-mediated nonsense mutation in medical patients

Country Status (10)

Country Link
US (1) US12458629B2 (enExample)
EP (2) EP3952867A4 (enExample)
JP (2) JP2022526643A (enExample)
KR (1) KR20210151131A (enExample)
CN (1) CN114007608A (enExample)
CA (1) CA3135641A1 (enExample)
EA (1) EA202192767A1 (enExample)
IL (1) IL287053A (enExample)
MX (1) MX2021012428A (enExample)
WO (1) WO2020210432A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102665711B1 (ko) * 2021-12-21 2024-05-14 재단법인 아산사회복지재단 Ras 활성도를 이용한 신경섬유종증 치료제에 대한 감수성 예측용 바이오마커 조성물 및 Ras 활성 억제제를 포함하는 신경섬유종증 예방 또는 치료용 약학적 조성물
WO2025110781A1 (ko) * 2023-11-24 2025-05-30 재단법인 아산사회복지재단 Ampd3를 포함하는 신경섬유종증 치료제에 대한 감수성 예측용 바이오마커 조성물 및 ampd3 저해제를 포함하는 신경섬유종증 예방 또는 치료용 약학 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2887054T3 (es) 2003-04-11 2021-12-21 Ptc Therapeutics Inc Compuesto de ácido 1,2,4-oxadiazol benzoico y su uso para la supresión sin sentido y el tratamiento de enfermedades
CA2603402C (en) 2005-04-08 2017-10-31 Ptc Therapeutics, Inc. Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
DE102005061832A1 (de) 2005-12-23 2007-06-28 Patent-Treuhand-Gesellschaft für elektrische Glühlampen mbH Hochdruckentladungslampe mit verbesserter Zündfähigkeit sowie Hochspannungspulsgenerator
IN2014CN04406A (enExample) * 2006-03-30 2015-09-04 Ptc Therapeutics Inc
PT2059513E (pt) 2006-09-08 2013-04-30 Ptc Therapeutics Inc Processo para a preparação de ácidos 1,2,4-oxadiazolebenzóicos
WO2008130370A1 (en) 2006-09-25 2008-10-30 Ptc Therapeutics, Inc. Hydroxylated 1,2,4-oxadiazole benzoic acid compounds, compositions thereof and the use for nonsense suppression
SG10201609581TA (en) 2006-09-25 2016-12-29 Ptc Therapeutics Inc Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid
CL2007002923A1 (es) 2006-10-12 2008-06-06 Ptc Therapeutics Inc Soc Organ Metodo para el tratamiento, prevencion o manejo de una enfermedad asociada con una mutacion sin sentido tal como cancer, diabetes o enfermedad pulmonar, que consiste en administrar a un paciente una cantidad efectiva de acido 3-[5-(2-fluoro-fenil)-[1
EP2203173B1 (en) * 2007-10-26 2015-12-23 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
ES2779302T3 (es) * 2013-09-04 2020-08-14 Cold Spring Harbor Laboratory Reducción de la degradación de ARNm con mediación sin sentido
TWI695717B (zh) * 2014-03-06 2020-06-11 美商 Ptc 治療公司 １,２,４-二唑苯甲酸之鹽及醫藥組合物
CN116196389A (zh) * 2016-01-06 2023-06-02 康德生物医疗有限公司 用于预防和治疗杜氏肌肉萎缩症的方法和组合物

Also Published As

Publication number Publication date
WO2020210432A8 (en) 2021-10-28
EA202192767A1 (ru) 2021-12-29
EP4473971A3 (en) 2025-02-19
WO2020210432A1 (en) 2020-10-15
JP2025160227A (ja) 2025-10-22
EP3952867A4 (en) 2023-01-11
CN114007608A (zh) 2022-02-01
US12458629B2 (en) 2025-11-04
MX2021012428A (es) 2022-01-19
JP2022526643A (ja) 2022-05-25
CA3135641A1 (en) 2020-10-15
KR20210151131A (ko) 2021-12-13
EP4473971A2 (en) 2024-12-11
EP3952867A1 (en) 2022-02-16
US20220175739A1 (en) 2022-06-09

Similar Documents

Publication Publication Date Title
SG11202107162UA (en) Plasma treatment device and plasma treatment method
GB2589250B (en) Medical image processing apparatus, medical image processing method and program
IL307937A (en) Treatment methods for muscular dystrophy
SG11201406430VA (en) Apparatus and method for endodontic treatment
GB202019972D0 (en) Floor treatment apparatus
SG10202011203SA (en) Plasma processing method and plasma processing apparatus
SG10202005364XA (en) Plasma processing method and plasma processing apparatus
EP4007540A4 (en) COLON TREATMENT METHODS AND APPARATUS
IL286460A (en) A method, a device for using graphene, and a used graphene product
ZA202106827B (en) Reagents for treatment of oculopharyngeal muscular dystrophy (opmd) and use thereof
CA235353S (en) Medical treatment apparatus
EP3162349A4 (en) Stretching massage apparatus for spine correction and muscle strengthening
GB201908246D0 (en) Touch-sensitive apparatus and method
SG11202108469XA (en) Compositions and methods for treating oculopharyngeal muscular dystrophy (opmd)
HK40066807A (en) Method for treating nonsense mutation mediated duchenne muscular dystrophy in pediatric patients
GB202204612D0 (en) Fuild treatment apparatus
EP3952867A4 (en) METHODS OF TREATMENT OF NONSENSE MUTATION MEDIATED DUCHENNE MUSCULAR DYSTROPHY IN PEDIATRIC PATIENTS
EP2536091A4 (en) METHOD AND DEVICE FOR PROCESSING THE MEETING DESCRIPTION PROTOCOL INQUIRY DURING THE OPTIMIZATION PROCEDURE OF THE MEDIA PATH
KR102315936B9 (ko) 하이브리드 수처리 장치 및 방법
IL262337A (en) Reagents for the treatment of oculo-pharyngeal muscular dystrophy (ompd) and their use
GB2593938B (en) Process and apparatus
GB2582930B (en) Induction heating method and apparatus
IL282323A (en) Methods for treating (OCULOPHARYNGEAL MUSCULAR DYSTROPHY (OPMD
GB202102026D0 (en) Medical apparatus and method
IL285129A (en) One-step gene therapy for Duchenne muscular dystrophy through gene replacement and anti-inflammation